{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:05:44Z","timestamp":1777791944379,"version":"3.51.4"},"posted":{"date-parts":[[2026,1,11]]},"group-title":"Psychiatry and Clinical Psychology","reference-count":42,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Traumatic brain injury (TBI) increases the risk of developing psychiatric symptoms such as post-traumatic stress disorder (PTSD), depression and anxiety, however biological risk and resiliency factors that explain the significant heterogeneity in outcomes are limited. Although 5-10% of the population carries natural autoantibodies to the NMDA receptor (anti-NMDAR1) it is unknown if carrying anti-NMDAR1 autoantibodies modifies risk for psychiatric outcomes after TBI.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Since TBI facilitates infiltration of circulating natural anti-NMDAR1 autoantibodies into the brain, we tested the hypothesis that natural anti-NMDAR1 autoantibody levels in plasma may modify risk for development of psychiatric symptoms after TBI.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design, Settings and Participants<\/jats:title>\n                  <jats:p>Data were analyzed from 1025 Marine Resiliency Study-II participants, a longitudinal study that included plasma collection and assessments for TBI, PTSD (Clinician Administered PTSD Scale-IV), depression (Beck Depression Inventory-2) and anxiety symptoms (Beck Anxiety Inventory) before and after a combat deployment to Afghanistan (2010-2013). Plasma anti-NMDAR1 autoantibody levels were quantified using a luciferase-based immunnoassay. Outcomes were post-deployment symptoms and the predictor was a continuous or dichotomous measure of anti-NMDAR1 autoantibody level. Covariates included pre-deployment symptoms, deployment history and experiences.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TBI (606 with TBI, 419 without TBI) was associated with significantly greater depression, PTSD and anxiety symptoms post-deployment. In individuals with no TBI history, anti-NMDAR1 autoantibody levels were not associated with symptoms. In individuals that endorsed a TBI however, higher pre-deployment plasma levels of natural anti-NMDAR1 autoantibodies were significantly associated with lower predicted post-deployment depression and PTSD symptoms, but not anxiety. In the TBI group, high autoantibody group membership lowered predicted post-deployment CAPS-IV and BDI-2 scores by 22 and 25% respectively (Cohen\u2019s d=0.25-0.32). After deployment, prevalence of moderate-severe depression was significantly lower in participants with high anti-NMDAR1 autoantibodies (.8% [2\/256 participants]) compared with participants with low anti-NMDAR1 autoantibodies (3.5% [27\/763 participants]), as was prevalence of taking psychotropic medications.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions and Relevance<\/jats:title>\n                  <jats:p>Natural anti-NMDAR1 autoantibodies may be a \u201cresilience\u201d factor for TBI-associated increases in depression and PTSD symptoms, supporting the hypothesis that natural anti-NMDAR1 autoantibodies could have neuroprotective effects. Mechanistic studies are warranted to understand if plasma natural anti-NMDAR1 autoantibodies reach the CNS to suppress glutamate excitotoxicity associated with TBI.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.01.08.26343690","type":"posted-content","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T11:30:12Z","timestamp":1768131012000},"source":"Crossref","is-referenced-by-count":1,"title":["Potential Neuroprotective Effects of Natural Anti-NMDAR1 Autoantibodies Against Psychiatric Symptoms Associated with Traumatic Brain Injuries"],"prefix":"10.64898","author":[{"given":"Melonie","family":"Vaughn","sequence":"first","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Acheson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"},{"name":"VA Center of Excellence for Stress and Mental Health VA San Diego Healthcare System San Diego, California, United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"},{"name":"VA Mental Illness Research and Clinical Core"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Yurgil","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, Loyola University, New Orleans LA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Nievergelt","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"},{"name":"VA Mental Illness Research and Clinical Core"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewleen","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Risbrough","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"},{"name":"VA Mental Illness Research and Clinical Core"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego La Jolla, California, CA 92093, United States of America"},{"name":"VA Mental Illness Research and Clinical Core"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026011210251886000_2026.01.08.26343690v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.3080"},{"key":"2026011210251886000_2026.01.08.26343690v1.2","doi-asserted-by":"publisher","DOI":"10.1080\/02699052.2017.1376756"},{"key":"2026011210251886000_2026.01.08.26343690v1.3","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1990.73.6.0889"},{"key":"2026011210251886000_2026.01.08.26343690v1.4","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1998.89.6.0971"},{"key":"2026011210251886000_2026.01.08.26343690v1.5","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2524102"},{"key":"2026011210251886000_2026.01.08.26343690v1.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5457.1453"},{"key":"2026011210251886000_2026.01.08.26343690v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.110"},{"key":"2026011210251886000_2026.01.08.26343690v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.06.015"},{"key":"2026011210251886000_2026.01.08.26343690v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-017-0011-3"},{"key":"2026011210251886000_2026.01.08.26343690v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.125"},{"key":"2026011210251886000_2026.01.08.26343690v1.11","doi-asserted-by":"publisher","DOI":"10.20900\/jpbs.20210009"},{"key":"2026011210251886000_2026.01.08.26343690v1.12","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19212"},{"key":"2026011210251886000_2026.01.08.26343690v1.13","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.16.25320688"},{"key":"2026011210251886000_2026.01.08.26343690v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00249-9"},{"key":"2026011210251886000_2026.01.08.26343690v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00282-7"},{"key":"2026011210251886000_2026.01.08.26343690v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2014.09.030"},{"key":"2026011210251886000_2026.01.08.26343690v1.17","doi-asserted-by":"publisher","DOI":"10.5888\/pcd9.110134"},{"key":"2026011210251886000_2026.01.08.26343690v1.18","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.4374"},{"key":"2026011210251886000_2026.01.08.26343690v1.19","unstructured":"Group DaVBICW. Acute Management of Mild Traumatic Brain Injury in Military Operational Settings: Clinical Practice Guidelines and Recommendations. 2006. December 22, 2006."},{"key":"2026011210251886000_2026.01.08.26343690v1.20","doi-asserted-by":"publisher","DOI":"10.1007\/BF02105408"},{"key":"2026011210251886000_2026.01.08.26343690v1.21","doi-asserted-by":"crossref","unstructured":"King DW , Leskin, G.A. , King, L.A. , Weathers, F.W. Confirmatory factor analysis of the clinician-administered PTSD Scale: Evidence for the dimensionality of posttraumatic stress disorder. Psychological Assessment. 1998;10","DOI":"10.1037\/\/1040-3590.10.2.90"},{"key":"2026011210251886000_2026.01.08.26343690v1.22","doi-asserted-by":"crossref","unstructured":"Weathers FW , Ruscio, A.M. Psychometric Properties of Nine Scoring Rules for the Clinician-Administered Posttraumatic Stress Disorder Scale. Psychological Assessment. 1999;11","DOI":"10.1037\/\/1040-3590.11.2.124"},{"key":"2026011210251886000_2026.01.08.26343690v1.23","doi-asserted-by":"crossref","unstructured":"Beck AT , Steer, R.A. , Brown, G.K. Manual for the Beck Depression Inventory-II. Psychological Corporation. 1996;","DOI":"10.1037\/t00742-000"},{"key":"2026011210251886000_2026.01.08.26343690v1.24","unstructured":"RA Bas . Beck Anxiety Inventory Manual. Psychological Corporation; 1993."},{"key":"2026011210251886000_2026.01.08.26343690v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/jts.21868"},{"key":"2026011210251886000_2026.01.08.26343690v1.26","doi-asserted-by":"publisher","DOI":"10.1186\/2041-2223-4-13"},{"key":"2026011210251886000_2026.01.08.26343690v1.27","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06091491"},{"key":"2026011210251886000_2026.01.08.26343690v1.28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04484"},{"key":"2026011210251886000_2026.01.08.26343690v1.29","doi-asserted-by":"publisher","DOI":"10.5271\/sjweh.3420"},{"key":"2026011210251886000_2026.01.08.26343690v1.30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2015.00172"},{"key":"2026011210251886000_2026.01.08.26343690v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109378"},{"key":"2026011210251886000_2026.01.08.26343690v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01266-9"},{"key":"2026011210251886000_2026.01.08.26343690v1.33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20230006"},{"key":"2026011210251886000_2026.01.08.26343690v1.34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22br14564"},{"key":"2026011210251886000_2026.01.08.26343690v1.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003414"},{"key":"2026011210251886000_2026.01.08.26343690v1.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256972"},{"key":"2026011210251886000_2026.01.08.26343690v1.37","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-018-0093-6"},{"key":"2026011210251886000_2026.01.08.26343690v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.05.005"},{"key":"2026011210251886000_2026.01.08.26343690v1.39","doi-asserted-by":"publisher","DOI":"10.2217\/imt.09.72"},{"key":"2026011210251886000_2026.01.08.26343690v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0895"},{"key":"2026011210251886000_2026.01.08.26343690v1.41","doi-asserted-by":"publisher","DOI":"10.20900\/jpbs.20230006"},{"key":"2026011210251886000_2026.01.08.26343690v1.42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02081-17"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.08.26343690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:25:30Z","timestamp":1768242330000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.01.08.26343690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":42,"URL":"https:\/\/doi.org\/10.64898\/2026.01.08.26343690","relation":{},"subject":[],"published":{"date-parts":[[2026,1,11]]},"subtype":"preprint"}}